Travere Therapeutics
NEWS
The FDA is likely to push back the Prescription Drug User Fee Act target action date for Travere Therapeutics’ sparsentan by three months..
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
With the turn of the calendar, biopharma and life sciences organizations have bolstered their leadership teams and board with these Movers & Shakers.
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.
Travere Therapeutics will also begin trading under the new ticker symbol, “TVTX” on the Nasdaq Global Select Market beginning on Nov. 19.
OT-58 is Orphan’s novel investigational enzyme replacement therapy. It is currently in Phase I/II development for classical HCU, a rare metabolic disorder marked by increased levels of plasma homocysteine.
The COVID-19 battle dominates the news, but it doesn’t constitute all the news. Here’s what several Southern California Biotech Beach companies are doing that you might have missed.
These prices refer to the company’s list price. Most patients will not pay that price because of various forms of health insurance or patient assistance programs.
These are the top biotech companies headquartered in Biotech Beach based on 2018 revenue. Here’s the brief information including the revenue of each company.
JOBS
IN THE PRESS